- •SGLT-2 inhibitors stimulate ketone reabsorption, increasing the risk of ketoacidosis.
- •Ketoacidosis with SGLT2 inhibitors is a relevant acidosis with mild hyperglycemia.
- •If the drug is properly prescribed, the risk of DKA is negligible in type 2 diabetes.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Diabetes Research and Clinical Practice
- Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.Cochrane Database Syst Rev. 2016; (Epub-ahead of print)
- Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.Drugs. 2015; 75: 33-59
- Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.N Engl J Med. 2015; 373: 2117-2128
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.Lancet Diabetes Endocrinol. 2016; 4: 411-419
- SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature.Pharmacotherapy. 2017; 37: 187-194
Food and Drug Administration. Safety Alert on Canagliflozin, issued on Oct 10th, 2015. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm461876.htm. Last accessed on 3rd August, 2016.
- Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition.Diabetes Care. 2015; 38: 1687-1693
- Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives.Diabetes Metab Res Rev. 2017; ([Epub ahead of print])
- Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.Ann Intern Med. 2009; 151: 264-269
- Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.Hosp Pract. 1995; 2013: 72-84
https://clinicaltrials.gov/ct2/show/NCT01032629?term=nct01032629&rank=1. Last accessed on 3rd August, 2016.
- Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.Curr Med Res Opin. 2016; 32: 427-439
- Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.Diabetes Obes Metab. 2014; 16: 124-136
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.Lancet Diabetes Endocrinol. 2014; 2: 369-384
- Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.Diabetes Care. 2014; 37: 1815-1823
- Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.Diabetes Care. 2015; 38: 420-428
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf. Last accessed on 3rd August, 2016.
- SGLT2 inhibitors may predispose to ketoacidosis.J Clin Endocrinol Metab. 2015; 100: 2849-2852
- Effect of sodium-glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta-analysis of randomized controlled trials.Diabetes Care. 2016; 39: e123-e124
http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Last accessed on 3rd August, 2016.
- Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors.Diabetes Care. 2015; 38: 1638-1642